Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 705 across all filing types
Latest filing 2025-01-06 Board/Management Inform…
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board Meeting scheduled to consider and approve the unaudited financial results for a specific quarter and nine months period. It also mentions the closure of the trading window for insiders. The document is an announcement of a future event (Board Meeting) and does not contain any financial data or results itself. It is not a full financial report, earnings release, or management discussion. The document fits the category of Board/Management Information (MANG) as it relates to the Board of Directors' meeting schedule and compliance with listing regulations.
2025-01-06 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of equity shares upon exercise of Employee Stock Option Plans (ESOPs). It details the number of shares allotted, the exercise price, premium, and the resulting total paid-up capital. The document includes annexures providing detailed compliance information as per SEBI regulations related to share-based employee benefits. There are no financial statements, earnings data, or management discussion and analysis. The content is focused on share allotment and capital changes due to ESOP exercises, which aligns with announcements about share issues or capital changes. The document length is 8685 characters, which is substantive and not a mere announcement of a report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-12-31 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the closure of the trading window pursuant to SEBI regulations ahead of the announcement of un-audited financial results for the quarter and nine months ended December 31, 2024. It does not contain any financial data or results itself, nor does it provide detailed financial analysis or reports. The document is essentially a regulatory compliance announcement related to insider trading restrictions before financial results are declared. Given its brevity (1301 characters) and nature as an announcement rather than a report, it fits best under Regulatory Filings (RNS).
2024-12-26 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) providing an update on an investment transaction involving the company's subsidiary. It references Regulation 30(7) of SEBI (LODR) Regulations, which pertains to disclosure of material events. The content is about a completed investment transaction by external investors into a subsidiary company. There is no financial report, earnings data, or management discussion. The document is an update on a capital transaction related to investment and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication or certification, so it is not RPA or RNS.
2024-12-20 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated December 6, 2024, announcing that Laurus Bio, a subsidiary of Laurus Labs, has secured equity investments from Eight Roads Ventures, F-Prime Capital, and Laurus Labs itself. The content focuses on the details of the equity investment transaction, including amounts, shareholding percentages, and strategic intentions. There are no financial statements, regulatory certifications, or detailed financial performance data included. The document is not an annual or interim report, audit report, or earnings release. It is an announcement related to capital raising and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7576 characters) supports it being a full announcement rather than a brief note or a report publication announcement.
2024-12-06 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the approval by the Board of Directors for an investment in a subsidiary company, Laurus Bio Private Limited, and details the investment amounts, shareholding percentages, and timelines. The document includes an annexure providing detailed information about the investment, the target entity, regulatory approvals, and other related party transaction disclosures. There is no financial statement or comprehensive financial report included; rather, it is an announcement of a capital investment and financing activity. This fits the category of Capital/Financing Update (CAP). The document length (6604 characters) and content confirm it is not a brief report publication announcement or a regulatory filing. Therefore, the classification is CAP with high confidence.
2024-12-06 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.